Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $20.40

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been assigned an average recommendation of “Hold” from the eight analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $20.40.

A number of research analysts have recently commented on KROS shares. Weiss Ratings cut Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $10.21 on Thursday. Keros Therapeutics has a 1 year low of $9.69 and a 1 year high of $22.55. The stock has a market capitalization of $202.06 million, a P/E ratio of -3.39 and a beta of 0.97. The company’s 50-day moving average is $10.79 and its 200 day moving average is $13.07.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The company had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million. Research analysts anticipate that Keros Therapeutics will post -5.19 earnings per share for the current year.

Insider Transactions at Keros Therapeutics

In other news, Director Alpna Seth sold 2,625 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.72, for a total value of $28,140.00. Following the sale, the director directly owned 9,767 shares of the company’s stock, valued at $104,702.24. This represents a 21.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of Keros Therapeutics stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the transaction, the director directly owned 9,767 shares of the company’s stock, valued at approximately $104,799.91. This trade represents a 21.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,425 shares of company stock valued at $89,994 in the last three months. 12.60% of the stock is currently owned by company insiders.

Institutional Trading of Keros Therapeutics

Hedge funds have recently made changes to their positions in the stock. Financial Management Professionals Inc. bought a new position in Keros Therapeutics during the 4th quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd boosted its holdings in Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after acquiring an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after acquiring an additional 1,888 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of Keros Therapeutics during the first quarter valued at $129,000. Finally, New York State Common Retirement Fund increased its holdings in shares of Keros Therapeutics by 264.1% during the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after acquiring an additional 7,700 shares in the last quarter. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.